Patients in Wales with a rare disease that causes epilepsy will be the first in the UK to get access to GW Pharma's cannabis-based medicine Epidyolex, after the drug was cleared for use by
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
